Evidence map›Paper›PMID 40072728›Full record

ArticleDrug delivery and translational research2025

Enhanced localized pressure-mediated non-viral gene delivery.

James E Dixon, Vanessa Wellington, Alaa Elnima, Amelie Savers, Lia A Blokpoel Ferreras, Aveen R Jalal, Hoda M Eltaher

Abstract read
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

James E DixonRegenerative Medicine & Cellular Therapies Division, School of Pharmacy, The University of Nottingham Biodiscovery Institute (BDI), University of Nottingham, Nottingham, NG7 2RD, UK. james.dixon@nottingham.ac.uk.ORCID 0000-0003-1225-3825
Vanessa WellingtonRegenerative Medicine & Cellular Therapies Division, School of Pharmacy, The University of Nottingham Biodiscovery Institute (BDI), University of Nottingham, Nottingham, NG7 2RD, UK.
Alaa ElnimaRegenerative Medicine & Cellular Therapies Division, School of Pharmacy, The University of Nottingham Biodiscovery Institute (BDI), University of Nottingham, Nottingham, NG7 2RD, UK.
Amelie SaversRegenerative Medicine & Cellular Therapies Division, School of Pharmacy, The University of Nottingham Biodiscovery Institute (BDI), University of Nottingham, Nottingham, NG7 2RD, UK.
Lia A Blokpoel FerrerasRegenerative Medicine & Cellular Therapies Division, School of Pharmacy, The University of Nottingham Biodiscovery Institute (BDI), University of Nottingham, Nottingham, NG7 2RD, UK.
Aveen R JalalRegenerative Medicine & Cellular Therapies Division, School of Pharmacy, The University of Nottingham Biodiscovery Institute (BDI), University of Nottingham, Nottingham, NG7 2RD, UK.
Hoda M EltaherRegenerative Medicine & Cellular Therapies Division, School of Pharmacy, The University of Nottingham Biodiscovery Institute (BDI), University of Nottingham, Nottingham, NG7 2RD, UK.ORCID 0000-0001-5602-2696

Funding

Biotechnology and Biological Sciences Research CouncilDefence Science and Technology Laboratory ACC6007330Engineering and Physical Sciences Research Council EP/F500491/1FP7 Ideas: European Research Council 227845Medical Research Council MR/K026682/1
6 · The paper itself

Abstract

Topically applied therapies must not only be effective at the molecular level but also efficiently access the target site which can be on milli/centimetre-scales. This bottleneck is particularly inhibitory for peptide and nucleic acid macromolecule drug delivery strategies, especially when aiming to target wounded, infected, and poorly perfused tissues of significant volume and geometry. Methods to drive fluid-flow or to enhance physical distribution of such formulations after local administration in accessible tissues (skin, eye, intestine) would be transformative in realizing the potential of such therapeutics. We previously developed a technology termed Glycosaminoglycan (GAG)-binding enhanced transduction (GET) to efficiently deliver a variety of cargoes intracellularly, using GAG-binding peptides and cell penetrating peptides (CPPs) in the form of nanoparticles. Herein, we demonstrate that the most simplistic GET formulation is relatively poor in diffusing into tissue matrix (tested in collagen scaffolds). Changing nanoparticle physicochemical properties can enhance penetration, however the use of a pressure differential, generating fluid-flow significantly enhances effective gene delivery over milli/centimetre scales. We adapted clinically used pressure systems to administer both negative (Negative pressure (NP) wound therapy; NPWT) and positive pressures (PP; Insufflator). Pressure differences generated enhanced distribution, and we were able to show for the first-time localized gene transfer in vitro in cell scaffolds and enhanced transfection of ex vivo skin explants. The ability to simply control intra-tissue localization of gene delivery on milli/centimetre scales using pressure application will facilitate new drug delivery strategies for accessible tissues. Importantly site-specific enhancement of penetration and activity of novel nanotechnologies and gene therapeutics could be transformative for future regenerative medicine strategies.

Indexed as

Gene Transfer TechniquesAnimalsCell-Penetrating PeptidesGlycosaminoglycansHumansNanoparticlesPressureCell-Penetrating PeptidesGlycosaminoglycansGAG-binding enhanced transduction (GET)Gene transferNegative pressure wound therapySkinTransfection

Identifiers

PMID40072728
PMCPMC12397159

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.